REGN-EB3: First Approval

REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in th...

Descripción completa

Detalles Bibliográficos
Autor principal: Markham, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799152/
https://www.ncbi.nlm.nih.gov/pubmed/33432551
http://dx.doi.org/10.1007/s40265-020-01452-3
_version_ 1783635103966035968
author Markham, Anthony
author_facet Markham, Anthony
author_sort Markham, Anthony
collection PubMed
description REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients.
format Online
Article
Text
id pubmed-7799152
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77991522021-01-12 REGN-EB3: First Approval Markham, Anthony Drugs AdisInsight Report REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in the Democratic Republic of Congo, REGN-EB3 was recently approved by the US FDA as a treatment for Ebola virus infection. This article summarizes the milestones in the development of REGN-EB3 leading to this first approval for the treatment of infection caused by Zaire ebolavirus (Ebola virus) in adult and paediatric patients. Springer International Publishing 2021-01-11 2021 /pmc/articles/PMC7799152/ /pubmed/33432551 http://dx.doi.org/10.1007/s40265-020-01452-3 Text en © Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle AdisInsight Report
Markham, Anthony
REGN-EB3: First Approval
title REGN-EB3: First Approval
title_full REGN-EB3: First Approval
title_fullStr REGN-EB3: First Approval
title_full_unstemmed REGN-EB3: First Approval
title_short REGN-EB3: First Approval
title_sort regn-eb3: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799152/
https://www.ncbi.nlm.nih.gov/pubmed/33432551
http://dx.doi.org/10.1007/s40265-020-01452-3
work_keys_str_mv AT markhamanthony regneb3firstapproval

Ejemplares similares